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Functional Characterization of Human Thyroid Tissue
with Immunohistochemistry
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Jean-Michel Bidart,2 and Martin Schlumberger3
Immunohistochemistry provides insights in the expression of functional proteins and of their localization in
normal thyroid tissue and in thyroid diseases. In hyperfunctional thyroid tissues, staining for sodium/iodide
symporter (NIS), pendrin, thyroid peroxidase (TPO), and thyroglobulin (Tg) is increased. In hypofunctioning
thyroid tissues, NIS staining is markedly decreased; in benign hypofunctioning adenomas, the expression of the
other functional proteins is unmodified or slightly decreased, whereas their expression is profoundly decreased
or absent in differentiated thyroid carcinoma.
Introduction
Immunohistochemistry studies the expression of pro-teins and their localization at the cellular and subcellular
level. The availability of a wide range of antibodies specifically
directed against antigens and cells permits to better define the
characteristics of tissues in health and diseases. Thyroid tissue
offers an example for applications of immunohistochemistry:
a large series of specific antigens are identified, specific anti-
bodies are available, and various thyroid diseases are charac-
terized.
This review describes advances afforded by immunohisto-
chemistry for the functional characterization of follicular thy-
roid cells in health and diseases. In this attempt, the review
focuses on the immunohistochemical evaluation of functional
thyroid proteins, such as enzymes involved in iodide transport
and organification and thyroid hormone production and se-
cretion. Oncogenic proteins, including ret, ras, and braf,
growth factors, and their receptors and signal transduction
pathways, which are known to be involved in thyroid tumor
development (1,2), are not treated and discussed in this review.
Beyond functional characterization, immunohistochemistry
may have other applications and may also afford diagnostic
and prognostic information.
Antibodies
Generation of specific polyclonal and=or monoclonal anti-
bodies against the protein of interest constitutes the basic step
in the development of immunohistochemical methods. The
protein can be purified from cell or tissue extracts or be pro-
duced from cloned cDNAs. In either case, large amounts of
antigenic material are needed to immunize either rabbits or
goats (0.5–5mg) for the production of polyclonal antibodies,
or mice (50–500 mg) for the generation of monoclonal anti-
bodies. Polyclonal antisera often display high affinity for their
corresponding antigen. However, limited quantities of anti-
bodies can be obtained from a single animal, and their speci-
ficity may be low when contaminants are co-purified with
the protein used for immunization. These limitations can be
overcome with the use of monoclonal antibodies, but their
production is more expensive and they usually display lower
affinities. Some immunohistochemical studies of the thyroid
gland are based on the use of monoclonal antibodies raised
against highly purified proteins, such as Tg or TPO (3,4).
Synthetic peptides representative of a given portion of the
protein of interest can also be used to generate antibodies
that bind specifically to the native molecule. In this case, short
(15- to 20-mer) synthetic peptides are generally conjugated
with large carrier proteins, such as albumin or hemocyanin,
to elicit a stronger immune response. This approach is par-
ticularly useful when the protein itself is not easily available.
It is difficult, for example, to purify sufficient quantities of
transmembrane proteins without altering their native confor-
mation. The primary structure of the putative protein must
be deduced from genome sequencing. Specific polyclonal or
monoclonal antibodies can be raised against the peptide and
used to identify the gene product in tissue specimens. This
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approach has been successfully used for the study of trans-
membrane glycoproteins that play critical functional roles in
the iodine metabolism of the thyrocyte, including the thyro-
tropin (thyroid-stimulating hormone) receptor (TSH-R), NIS,
the pendrin, the apical iodine transporter (AIT), and flavo-
proteins involved in the production of hydrogen peroxide
(dual oxidase [Duox]) (5–10). One major drawback for the
use of anti-peptide antibodies is their lower affinity for native
molecules compared to that of antibodies raised against the
native protein itself. Indeed, these antibodies that preferen-
tially bind to the denatured molecules are helpful for western
immunoblotting experiments and for immunohistochemistry.
Genetic immunization is apromisingmethod for generating
antibodies against putative proteins whose structures have
been deduced from the genome sequencing. An immune re-
sponse is elicited by injecting a eukaryotic expression vector
containing cDNA encoding the protein of interest, together
with a strong promoter. Intramuscular injection is followed by
a predominantly cellular response, while intradermal immu-
nization favors the humoral response. Both polyclonal and
monoclonal antibodies have been raised with this technique
against the native structure of NIS and TSH-R (11,12). This
technique is currently considered more reliable than immuni-
zation with natural or recombinant protein for generating anti-
bodies directed against conformationally determined epitopes.
Methods
For stabilizing cells in tissues and preventing alteration of
proteins by proteases, many fixative solutions can be used. For
a given antigen, preservation and revelation may strongly de-
pend on the fixation procedure used, and best results can be
obtained with one fixative and can be negative with another
one. Thus, for any new polyclonal or monoclonal antibody, a
large range of dilutions should be tested with different fixa-
tives. Formalin remains the best compromise under most cir-
cumstances. However, for some antibodies, better results were
obtained with Alcohol-Formol-Acetic-acid (AFA) or Bouin’s
fixative. The paraffin-embedded section, ranging 4–5mm thick,
is initially deparaffinized by serial passages in xylene and in
alcohol. Endogenous peroxidase activity is then quenched by
incubation in 0.03% hydrogen peroxide and 0.1M Tris-HCl
1buffer (pH 7.6) for 5 minutes, and the tissue is placed in
1mM ethylenediaminetetraacetic acid (EDTA) buffer (pH 8)
and subjected to microwave=pressure cooker pretreatment
(three cycles of 5minutes each). Alternatively, citrate is another
valid and commonly used buffer (pH 6). Frozen sections are
simply fixed in acetone for 10 minutes.
Sections are then incubated for 30–60 minutes at room
temperature with the primary monoclonal or polyclonal anti-
body. Following three 5-minute washes in the Tris-HCl 1
buffer, they are incubated for 15 minutes with enzyme con-
jugated antibodies directed against the primary antibody.
Several detection systems are available for immunohistochem-
istry, and those with peroxidase- or phosphatase-alkaline-
conjugated antibodies are the most frequently employed.
After three additional washes, binding is revealed with dia-
minobenzidine tetrahydrochloride with 0.1% hydrogen per-
oxide in Tris buffer 0.01M (pH 7.2) (peroxidase-conjugated
antibody) or BCIP=NTB (phosphatase-conjugated antibody).
Sections are counterstained with hematoxylin, dehydrated,
mounted, and examined under a microscope.
Double immunostaining
Double-immunostaining experiments are performed to in-
vestigate the localization of various antigens on the same
tissue sample. An example of double-staining experiments
reported is the study of NIS and pendrin localizations. This
procedure includes sequential steps: (a) slides are immuno-
stained with the anti-NIS rabbit antibody, as previously de-
scribed (a peroxidase-conjugated anti-rabbit antibody is used
as detection system); (b) after three washes, they are incu-
bated with the anti-pendrin mouse antiserum for 30 minutes;
(c) after three additional washes, sections are incubated with
a phosphatase-alkaline–conjugated anti-mouse monoclonal
antibody; (d) after three washes, phosphatase-alkaline staining
is revealed with BCIP=NTB; (e) slides are counterstained with
hematoxylin and mounted. In tissue, NIS immunostaining
appears brown and pendrin immunostaining, blue. Two types
of controls are performed on the same tissue samples and at
the same time as double immunostaining: (a) single immuno-
staining with each antiserum, and (b) single immunostaining
with the preimmune antisera.
Controls and validation of results
One limitation of immunohistochemistry is that negative
results may not reliably indicate the absence of the target pro-
tein. For this reason, sensitivity should always be verified by
including external and internal positive controls. The specificity
of the antigen-antibody binding should also be verified with
negative controls. Nonspecific reactions can be excluded by
using an irrelevant primary antibody, by incubating sections
with a preimmune antiserum, and by preabsorbing the pri-
mary antiserum with an excess of the corresponding peptide.
Cells transfected in vitro with the gene of interest can also be
used to provide both negative and positive controls.
Semiquantitative analysis of protein expression
Immunohistochemical techniques can demonstrate protein
expression and its localization within tissues or cells. Quan-
tification of the expression is more complicated, but staining
intensity and number of positive cells should be evaluated
on an adequate number of microscopic fields, and results are
commonly expressed in terms of semiquantitative scores for
each parameter.
Relationships with Other Methods
Immunohistochemistry is one of many techniques avail-
able for the study of protein expression that can be combined
to improve the reliability of results. Real-time kinetic quan-
titative PCR (RT-PCR), for example, is a highly sensitive tech-
nique for quantifying gene expression in terms of mRNA
product. RT-PCR and immunohistochemistry, when used to-
gether, provide an accurate characterization of gene expres-
sion at both mRNA and protein levels, and this may also
permit the study of posttranscriptional mechanisms.
Immunohistochemistry is extremely valuable for localizing
antigens of interest: it may identify thyroid follicles, intra-
follicular areas, and=or cell types expressing a given protein.
At the subcellular level, it may localize its expression within
the nucleus, cytoplasm, or membrane. Membrane localization
is particularly important in polarized cells, such as thyrocytes,
since basal, lateral, and apical membranes display the ex-
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pression of different proteins with specific functions that are
directly related to their location. Finally, direct relationships
can be found between staining patterns and biochemical ab-
normalities associated with thyroid diseases (see below).
Thyroid-Specific Genes
Biochemical pathways in thyrocytes
Thyroid organization. Functional thyroid tissue is com-
posed of follicles that are spheric structures containing the
colloid and lined by a monolayer of thyroid epithelial cells,
the thyrocytes. Functional studies with autoradiography and
ion mass spectrometry have shown a large heterogeneity
between follicles (13–15): small follicles lined by tall and cu-
boidal cells are considered active, and large follicles lined by
flattened cells are considered less active.
Iodine pathway. Thyrocytes are polarized cells, with a
basal membrane in contact with vessels and an apical mem-
brane in contact with the follicular lumen that contains the
colloid. Iodide is first concentrated from the blood across the
basolateral cell membrane of the thyrocyte. It then moves to-
ward the apical pole and crosses the apical membrane to reach
the follicular lumen. Organification of iodide in Tg mole-
cules occurs at the external side of the apical membrane. The
iodinated Tg (Tg-I) is then stored in the follicular lumen. In
normal follicles, Tg-I is integrated in the thyrocyte by an en-
docytic process. Tg-I undergoes proteolytic cleavage inside
the thyrocyte to produce both thyroid hormones that are se-
creted into the bloodstream and iodotyrosines that are deio-
dinated by a deshalogenase (16).
Iodide transport involves several proteins. At the basolat-
eral membrane, the sodium=iodide symporter (NIS, SLC5A5)
actively co-transports Naþ and I from the blood into the thy-
rocyte (7,17,18). At the apicalmembrane, other transportersmay
facilitate the efflux of iodide into the follicular lumen, but the
role of two apical proteins, namely the pendrin (PDS gene,
SLC26A4) and the apical iodine transporter (AIT, SLC5A8), is
still not known (8,9,19,20). Incorporation of iodide into tyrosyl
residues of the Tgmolecule and coupling of iodotyrosyl residues
are both catalyzed by thyroid peroxidase (TPO) in the pres-
ence of hydrogen peroxide (H2O2) (21,22). The H2O2 generation
is catalyzed by Duox, an Nicotinamide Adenine Dinucleotide
Phosphate (NADPH)membrane–boundthyroidoxidase (10,23).
Polyclonal and monoclonal antibodies have been raised
against each of these proteins (Table 1), and immunohisto-
chemistry allowed the study of their expression in normal
and tumor thyroid tissues.
Regulation pathway. The primary regulator of thyroid
cell function is TSH. TSH binding to its membrane receptor
on thyroid cells activates the cAMP cascade, with consequent
upregulation of thyroid transcription factor-1 (TTF1), thyroid
transcription factor-2 (TTF2), and human paired-box-protein
(PAX8). These transcription factors enhance the expression of
NIS, TPO, Tg, and TSH-R genes by binding to their specific
promoters (24–28).
Immunohistochemical characterization of
thyroid tissues
Normal thyroid tissue. NIS staining is restricted to the
basolateral membrane (7), whereas staining for pendrin and
AIT is limited to the apical membrane (8,29; Fig. 1A–C).
Staining for NIS, pendrin, and AIT is heterogeneous. Some
follicles are negative, and within positive follicles, only a mi-
nority of cells are stained: less than 25% of normal thyrocytes
display staining for NIS, 30% to 50% for pendrin, and 10% to
40% for AIT. NIS staining is observed in some tall thyrocytes
that are considered active. A small number of NIS-positive
cells are contiguous and define a particular functioning area of
the follicle that is close to blood vessels (Fig. 1A, superposed
cut). In contrast, NIS staining is not detected in flattened
thyrocytes that are considered inactive (7,29). A similar picture
is observed for pendrin, but follicular cells are more frequently
positive for pendrin than for NIS.
TPO staining is homogeneous in the cytoplasm of the
majority of thyroid cells, and is more intense at the apical
membrane (4,30,31; Fig. 1D). Staining tends to be more in-
tense in small follicles composed of tall thyrocytes than in
larger ones surrounded by flattened cells (30). Duox expres-
sion is found in the majority of tall follicular cells, and is
located at the apical membrane, whereas most flattened cells
are negative (10,31; Fig. 1E).
Tg and Tg-I staining is intense in the lumen of all follicles.
Follicular cells can be Tg negative=Tg-I negative, Tg positive=
Tg-I negative, or Tg positive=Tg-I positive, probably reflec-
ting their functional status, being resting, Tg-synthetizing, or
hormone-producing cells, respectively (31; Fig. 1F, G).
TSH-R staining is present in all thyrocytes, and is re-
stricted to the basal membrane and to a lesser extent to the
lateral membrane (5,31; Fig. 1H).
Table 1. Antibodies Directed Against Thyroid Antigens Used at IGR
Antigen Antibody Dilution Source
NIS SLC5A5 Polyclonal 1859 1=500 J.M. Bidart (IGR)
Pendrin SLC26A4 Monoclonal (PDS 02) 1=25 J.M. Bidart (IGR)
AIT SLC5A8 Monoclonal (AIT 01) 1=500 J.M. Bidart (IGR)
TPO Monoclonal (TPO 47) 1=4 Biocytex
Duox Polyclonal 2776 1=250 A. Virion (IGR)
Thyroglobulin Monoclonal (TG tg6) 1=100 DAKO
Thyroxine Polyclonal 1=100 Biogenesis
TSH-R Monoclonal (TSH-R 365) 1=250 E. Milgrom (Paris Sud)
TTF1 Monoclonal (TTF1 8G7G3=1) 1=100 DAKO
IGR: Institut Gustave Roussy; NIS: sodium=iodide symporter; AIT: apical iodine transporter; TPO: thyroid peroxidase; Duox: dual oxidase;
TSH-R: thyroid-stimulating hormone receptor; TTF1: thyroid transcription factor-1.
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Staining for NIS, pendrin, AIT, TPO, Duox, Tg, Tg-I, and
TSH-R is restricted to thyrocytes: antibodies do not react with
lymphocytes, macrophages, vascular endothelial cells, or any
stromal cell.
The percentage of thyrocytes stained for NIS, pendrin, and
Duox is higher in thyroid tissues obtained in children less
than 12 years of age. This is in agreement with the higher
percentage of small follicles with tall or cuboidal cells ob-
served during childhood. Staining for AIT and TPO does not
vary with age (32).
Among thyroid transcription factors, TTF1 is the most well
characterized. The majority of nuclei of normal thyroid tissue
are strongly stained (Fig. 1I) (33).
Diffuse thyroid hyperplasia. The thyroid gland is in-
creased in size and may contain nodules. Staining is highly
variable. NIS and pendrin staining is usually restricted to
defined areas inside a follicle constituted by tall thyrocytes
that are close to vessels (7,8). TSH-R and TPO staining is
positive in virtually all thyrocytes (31). Tg staining is similar to
FIG. 1. Immunohistochemical expression of the biochemical pathway of thyrocytes in normal thyroid tissue (magnification,
200): (A) Sodium=iodide symporter (NIS) staining at the basolateral membrane; (B) pendrin staining at the apical mem-
brane; (C) apical iodine transporter staining at the apical membrane; (D) thyroid peroxidase cytoplasmic staining associated
to an apical membrane reinforcement; (E) dual oxidase staining at the apical membrane; (F) thyroglobulin (Tg) staining in the
lumen of follicles and in most follicular cells; (G) iodinated Tg staining in the lumen of follicles and in most follicular cells;
(H) thyroid-stimulating hormone receptor staining at the basolateral membrane; (I) thyroid transcription factor-1 staining in
most nuclei; (superposed cut in A) NIS-positive thyrocytes contiguous to blood vessels (magnification,1000).
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that observed in normal thyroid tissue. Staining for Duox
varies widely between follicles, but the average number of
positive cells is similar to that of normal tissues (10). NIS,
pendrin, and Duox staining is detected in the majority of
thyrocytes of small follicles.
Graves’ disease and toxic adenoma. NIS and pendrin
staining is present in most follicular cells, with a stronger
intensity than in normal tissue samples (Table 2; Fig. 2A, B)
(7,8) whereas AIT expression is similar or slightly decreased
as compared to normal thyroid tissue (29). Staining for NIS is
present not only on latero-basal membrane but also, with a
weaker intensity, in the cytoplasm (Fig. 2C). Double-staining
experiments indicate that NIS-positive=pendrin-positive thy-
rocytes (arrows) alternate with NIS-negative=pendrin-positive
thyrocytes (34; Fig. 2D). TPO staining is stronger in all thyro-
cytes than in normal thyroid tissue (30,31). Tg, Tg-I, and TSH-R
stainings are generally stronger than in normal thyroid tissue
(5,31), whereas Duox staining is found only in few cells and
with a much weaker intensity than in normal tissue (10).
Autoimmune thyroiditis. Staining for NIS and pendrin is
found in a percentage of cells similar to normal thyroid tissue,
but the distribution of positive cells is peculiar: thyrocytes
in contact with lymphocytes are strongly stained, while the
others are either negative or only weakly positive (7). In
contrast, TPO, Tg, TSH-R, and Duox staining is similar to that
observed in normal thyroid tissue in all thyrocytes, either in
contact or not in contact with lymphocytic infiltrates.
Hypofunctioning follicular adenoma. NIS staining is to-
tally negative in about 2=3 of hypofunctioning adenomas; in
the remaining third, fewer than 20% of the cells are stained
(7) (Table 2). Pendrin expression is similar to normal tissues
in 3=4 of cases, and is weak or even absent in the remaining
samples that are also NIS-negative (8). AIT is expressed in a
lower number of follicles and thyrocytes than in normal
thyroid tissue, but stronger staining, similar to that found in
normal thyroid tissue, is found in microfollicular adenomas
and Hu¨rthle cell tumors (29). TPO is generally expressed, but
rare benign tumors are negative or weakly stained (30,31).
Staining for Tg and TSH-R is similar to normal thyroid tissue
(5,31). Duox staining varies widely between adenomas and is
related to follicle size, ranging from weak staining in a mi-
nority of cells in macrofollicular areas to diffuse and intense
staining in microfollicular areas (10).
Papillary and follicular thyroid carcinomas. NIS and pen-
drin staining is totally negative in about 80% of differenti-
ated thyroid cancers (7,8). In positive samples, only rare
cancer cells are NIS-positive, and a somewhat higher number
of cells are pendrin-positive (Table 2; Fig. 3A, B). Interest-
ingly, in papillary thyroid carcinomas that express these
proteins, NIS staining is found in the basolateral membrane
that is in contact with the vascular core of the papillae, while
pendrin is found at the opposite pole, confirming the polar-
ization of these tumor cells. In some studies, an unexpected
increased NIS expression was reported in up to 2=3 of the
papillary thyroid carcinomas, with staining found in the intra-
cellular compartments and in some cases also in the plasma
membrane (31,35). In some studies, cytoplasmic NIS staining
was considered artifactual since it was found in paraffin-
embedded sections but not on cryostat-frozen sections (7). In
addition, the mature NIS protein was not detected by im-
munoblot experiments in hypofunctioning thyroid tumors,
and small amounts of nonglycosylated NIS proteins that were
localized in the intracellular compartments were found in
NIS transcript positive tumors (36–40). This shows abnor-
malities in NIS posttranscriptional maturation and targeting
to the plasma membrane and may explain NIS positivity
at immunohistochemistry. Similarly, pendrin staining was
found in more than 70% of differentiated thyroid carcinomas
at the cytoplasmic level only (41). AIT staining is negative in
most differentiated thyroid carcinomas (Fig. 3C).
Positive polyclonal antibody staining for TPO is observed
in more than 50% of papillary carcinomas. However, staining
with the monoclonal antibody MoAb47 is weak or absent in
the large majority of papillary and follicular thyroid carcino-
mas, reflecting both a decreased expression and structural
abnormalities in the TPO molecule (4,30; Fig. 3D).
Duox staining is found in almost 80% of papillary and
follicular thyroid carcinomas (42). Staining is found in both
the cytoplasm and the apical membrane of cancer cells (Fig.
3E, F). Among positive tumors, the percentage of stained
Table 2. Expression Level of Functional Thyroid Proteins as Shown by Immunohistochemistry in
Graves’ Disease, Hypofunctioning Follicular Adenoma, and Differentiated Thyroid Carcinoma,
as Compared to Normal Thyroid Tissue
Antigen Graves’ disease
Hypofunctioning
follicular adenoma
Differentiated thyroid
carcinoma
NIS (SLC5A5) Increased Decreased Decreased or absent
Pendrin (SLC26A4) Increased Unmodified or decreased Decreased or absent
AIT (SLC5A8) Unmodified or decreased Unmodifieda or decreased Decreased or absent
TPO Increased Unmodified or decreased Decreased or absent
Duox Decreased Unmodifieda or decreased Decreased, only rarely absent
Tg Increased Unmodified or decreased Decreased
Tg-I Increased Unmodified Absent
TSH-R Increased Unmodified Decreased
TTF1 Unmodified Unmodified Increased
aIn microfollicular and Hurthle cell adenoma.
NIS: sodium=iodide symporter; AIT: apical iodine transporter; TPO: thyroid peroxidase; Duox: dual oxidase; Tg: thyroglobulin;
Tg-I: iodinated Tg; TSH-R: thyroid-stimulating hormone receptor; TTF1: thyroid transcription factor-1.
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follicular cells is highly variable. Among patients with distant
metastases, Duox staining is positive in all tumors with 131I
uptake and in only half of tumors with no demonstrable 131I
uptake. Among Duox positive thyroid tumors, fewer than
10% are stained for NIS, 40% for pendrin, and 50% for TPO.
In contrast, all Duox negative thyroid tumors are also nega-
tive for NIS and pendrin, and only 20% are positive for TPO.
Tg staining is detected in all differentiated thyroid carci-
nomas, but its intensity is lower than in normal thyroid tissue
(43). Tg-I staining is absent in all thyroid cancer tissues (31),
depicting a characteristic Tg-positive=Tg-I-negative picture
(Fig. 3G, H).
TSH-R staining in well-differentiated and minimally in-
vasive follicular carcinomas is more heterogeneous and
weaker than in hypofunctioning adenomas and in normal
thyroid tissue (44), and is present only at the cytoplasmic
level (5). In papillary carcinomas, TSH-R staining varies
widely from one area to another, and within positive areas,
cells are either positive or negative. When present, staining is
restricted to the basolateral membrane in contact with the
vascular core of the papillae, confirming the polarization of
these cells (31).
TTF1 is strongly expressed in differentiated thyroid tumors
(33,45; Fig. 3I). In papillary thyroid carcinoma, TTF1 staining is
increased in aggressive tumors (46,47).
In poorly differentiated and widely invasive follicular
thyroid carcinomas, no staining is observed for NIS, pendrin,
AIT, and TPO. Tg staining is observed in only a minority of
cells, and TSH-R staining is weaker and more heterogeneous
than in well-differentiated tumors. Duox staining is found at
the apical membrane and in the cytoplasm in a minority of
cases. A low TTF1 staining is found in 25% to 42% of cases
(33,45).
FIG. 3. Immunohistochemical studies in differentiated
thyroid cancer. (A) Sodium=iodide symporter negative
staining in all tumor cells in a papillary thyroid carcinoma
(magnification,200); (B) pendrin positive staining in a mi-
nority of tumor cells in a papillary thyroid carcinoma (mag-
nification, 200); (C) apical iodine transporter negative
staining in all tumor cells in a papillary thyroid carcinoma
(magnification,200); (D) thyroid peroxidase negative stain-
ing in all tumor cells in a papillary thyroid carcinoma (mag-
nification,100); (E) dual oxidase (Duox) positive staining at
the apical membrane and in the cytoplasm in a papillary
thyroid carcinoma (magnification, 100); (F) Duox negative
staining in all tumor cells in a papillary thyroid carcinoma
(magnification,100); (G) thyroglobulin (Tg) positive staining
in only few follicles and thyrocytes in a follicular thyroid
carcinoma, and highly positive Tg staining in normal thyroid
tissue (magnification,100); (H) iodinated Tg negative stain-
ing in a follicular thyroid carcinoma and positive staining in
normal thyroid tissue (magnification,100); (I) thyroid tran-
scription factor-1 positive staining in all tumor cell nuclei in a
follicular thyroid carcinoma (magnification,100).
FIG. 2. Immunohistochemical expression of sodium=iodide
symporter (NIS) and pendrin in Graves’ disease. (A) NIS and
(B) pendrin stainings are stronger than in normal thyroid tis-
sue (magnification,200). (C) NIS localization at the basolateral
membrane and in the cytoplasm of thyrocytes (magnification,
400). (D) Double-stained thyrocytes with NIS in brown and
pendrin in blue: NIS-positive=pendrin-positive thyrocytes
(arrows) alternate with NIS-negative=pendrin-positive thyro-
cytes (arrowheads) (magnification,400).
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In anaplastic carcinomas, there is no detectable staining
for NIS, pendrin, TPO, Tg, and TSH-R (48), and only focal
staining for TTF1 (45). Tg staining, when present, is related
to a diffusion of Tg from a differentiated component or to
entrapped differentiated follicular cells.
Implications of immunohistochemistry
Pathophysiology. The localization of thyroid-specific
proteins (basolateral for NIS and TSH-R, and apical for pen-
drin, AIT, TPO, and Duox) is closely related to their func-
tional roles. Various expression patterns are observed among
follicles in normal thyroid tissues and are in close accor-
dance with their iodine concentrating ability, as shown by
autoradiography and ion microscopy (13–15). Staining for
NIS, pendrin, and Duox thus differentiates between active
follicles, small follicles composed of tall=cuboidal thyrocytes,
which are characterized by a strong expression of these pro-
teins, and follicles with a depressed functional activity, which
are larger in size and with flattened thyrocytes and that ex-
press these proteins either weakly or not at all (32). In con-
trast, TPO, Tg, and TSH-R expression is not related with the
morphological features of the thyrocytes or follicles.
Abnormal expression of thyroid-specific proteins is closely
related to various defects of iodine metabolism that charac-
terize neoplastic follicular cells, for example, decreased iodide
concentration, decreased iodide organification, and low rate
of Tg iodination and of hormone synthesis (36–39). When no
iodide uptake is found in the metastases, staining for NIS
and pendrin is absent, and when iodide uptake is found, NIS
staining is highly variable between studies, and these dis-
crepancies may be related to the antibody used. One study
using an NIS monoclonal antibody in recurrent differenti-
ated thyroid cancer highlighted a positive predictive value of
79% of NIS staining on 131I uptake and a negative predictive
value of 62%, while another study using a polyclonal anti-
body highlighted a positive predictive value of 100% and a
negative predictive value of 46% (35,49).
TSH-R staining is detected in most thyroid carcinomas,
and this is consistent with in vivo findings that demonstrate
that all papillary and follicular thyroid carcinomas are TSH
sensitive, and confirms the need of treating all these patients
with thyroxine (7,31,44).
Immunohistochemical findings at the protein level and
results of quantitative RT-PCR or northern blots at the RNA
messenger level indicate that alterations of iodine metabolism
in thyroid tumors are related to alterations in gene expres-
sion, and that abnormalities in posttraductional maturation
and targeting to the plasma cell membrane may also exist.
NIS expression is increased in hyperfunctioning thyroid tis-
sues and decreased in both benign and malignant hypofunc-
tioning thyroid tumors. TPO expression is decreased in
malignant tumors and is normal in benign tumors, while Duox
expression is increased in some hypofunctioning thyroid tu-
mors, either benign or malignant. These observations clearly
show that the mechanisms regulating Duox expression are dif-
ferent from those controlling the expression of other thyroid-
specific proteins. In anaplastic thyroid carcinomas, none of the
thyroid-specific proteins are significantly expressed.
Diagnosis of thyroid cancer. Tg is expressed in all dif-
ferentiated tumors of follicular origin, both benign and ma-
lignant, and is the most useful marker for confirming the
follicular origin of any thyroid tumor, with a specificity and a
sensitivity close to 100% (44). Tg immunostaining is partic-
ularly useful for confirming the thyroid follicular origin of
atypical tumors (primary thyroid tumors or undiagnosed
tumors of the neck) and of distant metastases (50).
Immunohistochemistry has also proved to be useful for the
diagnosis of benign and malignant follicular tumors. Indeed,
in malignant thyroid tumors, an abnormal TPO structure re-
sults in a lower affinity for the monoclonal antibody MoAb47,
and negative TPO staining is considered a marker of malig-
nancy in follicular cell–derived tumors, both on cytological
and histological specimens (4,30).
In normal and hyperplastic tissues, the distribution of TTF-1
correlates to that of thyroid-specific proteins, while a hetero-
geneous distribution occurs in thyroid tumors (33,47). In dif-
ferentiated thyroid cancers, the nuclear TTF-1 staining seems
to predict tumor recurrence (46). Anaplastic thyroid carcinoma
is negative for all thyroid-specific proteins, including TTF1,
and positive for cytokeratins. Therefore, immunostaining is
used in this case to exclude the diagnosis. Negative staining for
calcitonin and carcinoembryonic antigen permits the exclusion
of a medullary thyroid carcinoma, and negative staining for
the common leukocyte antigen (CLA) permits the exclusion of
a malignant lymphoma (51).
Biomarker conservation in primary and in metastatic
thyroid tumors. In a limited number of studies, there is no
significant difference in the expression of thyroid-specific
proteins between the primary thyroid tumor and in the cor-
responding lymph node metastases. Similarly, when distant
metastases are present, they are consistently positive for Tg
expression (31).
Acknowledgments
This study was partially supported by the ‘‘Fondazione
Umberto Di Mario ONLUS.’’
References
1. Fagin JA 1994 Molecular genetics of human thyroid neo-
plasms. Annu Rev Med 45:45–52.
2. Santoro M, Melillo RM, Fusco A 2006 RET=PTC activation in
papillary thyroid carcinoma: European Journal of Endocri-
nology Prize Lecture. Eur J Endocrinol 155:645–653.
3. Bellet D, Schlumberger M, Bidart JM, Assicot M, Caillou B,
Motte P, Vignal A, Bohuon C 1983 Production and in vitro
utilization of monoclonal antibodies to human thyroglobulin.
J Clin Endocrinol Metab 56:530–533.
4. De Micco C, Kopp F, Vassko V, Grino M 2000 In situ hybrid-
ization and immunohistochemistry study of thyroid peroxi-
dase expression in thyroid tumors. Thyroid 10:109–115.
5. Mizukami Y, Hashimoto T, Nonomura A, Michigishi T,
Nakamura S, Noguchi M, Matsukawa S 1994 Immunohisto-
chemical demonstration of thyrotropin (TSH)-receptor in
normal and diseased human thyroid tissues using monoclo-
nal antibody against recombinant human TSH-receptor pro-
tein. J Clin Endocrinol Metab 79:616–619.
6. Castro MR, Berger ER, Beito TG, McIver B, Goellner JR,
Morris JC 1999 Development of monoclonal antibodies
against the human sodium iodide symporter: immunohisto-
chemical characterization of this protein in thyroids cells.
J Clin Endocrinol Metab 84:2957–2962.
IMMUNOHISTOCHEMISTRY IN THYROID DISEASES 209
7. Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlum-
berger M, Bidart JM 1998 Naþ=I symporter distribution
in human thyroid tissues: an immunohistochemical study.
J Clin Endocrinol Metab 83:4102–4106.
8. Bidart JM, Mian C, Lazar V, Russo D, Filetti S, Caillou B,
Schlumberger M 2000 Expression of Pendrin and the Pen-
dred syndrome (PDS) gene in human thyroid tissues. J Clin
Endocrinol Metab 85:2028–2033.
9. Rodriguez AM, Perron B, Lacroix L, Caillou B, Leblanc G,
Schlumberger M, Bidart JM, Pourcher T 2002 Identification
and characterization of a putative human iodide transporter
located at the apical membrane of thyrocytes. J Clin Endo-
crinol Metab 87:3500–3503.
10. Caillou B, Dupuy C, Lacroix L, Nocera M, Talbot M, Ohayon
R, Deme D, Bidart JM, Schlumberger M, Virion A 2001
Expression of reduced nicotinamide adenine dinucleotide
phosphate oxidase (ThoX, LNOX, Duox) genes and proteins in
human thyroid tissues. J Clin Endocrinol Metab 86:3351–3358.
11. Costagliola S, Rodien P, Many MC, Ludgate M, Vassart G
1998 Genetic immunization against the human thyrotropin
receptor causes thyroiditis and allows production of mono-
clonal antibodies recognizing the native receptor. J Immunol
160:1458–1465.
12. Costagliola S, Many MC, Denef JF, Pohlenz J, Refetoff S,
Vassart G 2000 Genetic immunization of outbred mice with
thyrotropin receptor cDNA provides a model of Graves’
disease. J Clin Invest 105:803–811.
13. Studer H, Forster R, Conti A, Kohler H, Haeberli A, Engler
H 1978 Transformation of normal follicles into thyrotropin
refractory ‘‘cold’’ follicles in the aging mouse thyroid gland.
Endocrinology 102:1576–1586.
14. Mestdagh C, Many MC, Halpern S, Briancon C, Fragu P,
Denef JF 1990 Correlated autoradiografic and ion-microscopic
study of the role of iodine in the formation of ‘‘cold’’ follicles in
young and old mice. Cell Tissue Res 260:449–457.
15. Schu¨rch M, Peter HJ, Gerber H, Studer H 1990 Cold follicles
in a multinodular goiter arise partly from a failing iodide
pump and partly from deficient iodine organification. J Clin
Endocrinol Metab 71:1224–1229.
16. Dunn AD 2000 Thyroglobulin: chemistry, biosynthesis, and
proteolysis. In: Braverman LE, Utiger RD (eds) Werner and
Ingbar’s the Thyroid, 8th edition. Lippincott Williams &
Wilkins, Philadelphia, pp 91–104.
17. Dai G, Levy O, Carrasco N 1996 Cloning and characteriza-
tion of the thyroid iodide transporter. Nature 379:458–460.
18. Smanik PA, LiuQ, Furminger TL, RyuK-Y, Xing S,Mazzaferri
EL, Jhiang SM 1996 Cloning of the human sodium iodide
symporter. Biochem Biophys Res Commun 226:339–345.
19. Scott DA, Wang R, Kreman TM, Sheffield VC, Karnishki LP
1999 The Pendred syndrome gene encodes a chloride-iodide
transport protein. Nat Genet 21:440–443.
20. Royaux IE, Suzuki K, Mori A, Katoh R, Everett L, Kohn LD,
Green E 2000 Pendrin, the protein encoded by the Pendred
syndrome (PDS) gene, is an apical porter in the thyroid and
is regulated by thyroglobulin in FRTL-5 cells. Endocrinology
141:839–845.
21. Taurog A 2000 Hormone synthesis: thyroid iodine metabo-
lism. In: Braverman LE, Utiger RD (eds) Werner and Ingbar’s
the Thyroid, 8th edition. Lippincott Williams & Wilkins,
Philadelphia, pp 61–85.
22. Corvilain B, Van Sande J, Laurent E, Dumont JE 1991 The
H2O2-generating system modulates protein iodination and
the activity of the pentose phosphate pathway in dog thy-
roid. Endocrinology 128:779–785.
23. Leseney AM, De`me D, Legue O, Ohayon R, Chanson P, Sales
JP, Pires de Carvalho D, Dupuy C, Virion A 1999 Biochemi-
cal characterization of a Ca2þ=NAD(P)H-dependent H2O2-
generator in human thyroid tissue. Biochimie 81:373–380.
24. Trueba SS, Auge J, Mattei G, Etchevers H, Martinovic J,
Czernichow P, Vekemans M, Polak M, Attie-Bitach T 2005
PAX8, TITF1, and FOXE1 gene expression patterns during
human development: new insights into human thyroid de-
velopment and thyroid dysgenesis-associated malformations.
J Clin Endocrinol Metab 90:455–462.
25. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R,
Damante G 1994 Expression of thyroid-specific transcription
factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer
Res 54:4744–4749.
26. Ohmori M, Endo T, Harii N, Onaya T 1998 A novel thyroid
transcription factor is essential for thyrotropin-induced up-
regulation of Naþ=I symporter gene expression. Mol Endo-
crinol 12:727–736.
27. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlum-
berger M 1999 Sodium iodide symporter: a key transport
system in thyroid cancer cell metabolism. Eur J Endocrinol
141:443–457.
28. Jhiang SM, Cho JY, Ryu KY, DeYoung BR, Smanik PA,
McGaughy VR, Fisher AH, Mazzaferri EL 1998 An immuno-
histochemical study of Naþ=I symporter in human thyroid
tissues and salivary gland tissues. Endocrinology 139:4416–
4419.
29. Lacroix L, Pourcher T, Magnon C, Bellon N, Talbot M, In-
taraphairot T, Caillou B, Schlumberger M, Bidart JM 2004
Expression of the apical iodide transporter in human thyroid
tissues: a comparison study with other iodide transporters.
J Clin Endocrinol Metab 89:1423–1428.
30. De Micco C, Ruf J, Chrestian MA, Gros N, Henry JF, Cara-
yon P 1991 Immunohistochemical study of thyroid peroxi-
dase in normal, hyperplastic, and neoplastic human thyroid
tissues. Cancer 67:3036–3041.
31. Gerard AC, Daumerie C, Mestdagh C, Gohy S, De Burbure
C, Costagliola S, Miot F, Nollevaux MC, Denef JF, Rahier J,
Franc B, De Vijlder JJ, Colin IM, Many MC 2003 Correla-
tion between the loss of thyroglobulin iodination and the
expression of thyroid-specific proteins involved in iodine
metabolism in thyroid carcinomas. J Clin Endocrinol Metab
88:4977–4983.
32. Faggiano A, Coulot J, Bellon N, Talbot M, Caillou B, Ricard
M, Bidart JM, Schlumberger M 2004 Age-dependent varia-
tion of follicular size and expression of iodine transporters in
human thyroid tissue. J Nucl Med 45:232–237.
33. Katoh R, Kawaoi A, Miyagi E, Li X, Suzuki K, Nakamura Y,
Kakudo K 2000 Thyroid transcription factor-1 in normal,
hyperplastic, and neoplastic follicular thyroid cells examined
by immunohistochemistry and nonradioactive in situ hybrid-
ization. Mod Pathol 13:570–576.
34. Mian C, Lacroix L, Alzieu L, Nocera M, Talbot M, Bidart JM,
Schlumberger M, Caillou B 2001 Sodium iodide symporter and
pendrin expression inhuman thyroid tissues. Thyroid11:825–830.
35. Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC 2001
Immunohistochemical analysis of sodium iodide symporter
expression in metastatic differentiated thyroid cancer: cor-
relation with radioiodine uptake. J Clin Endocrinol Metab
86:5627–5632.
36. Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaol A,
Muramatsu A, Onaya T 1998 Increased expression of the
sodium=iodide symporter in papillary thyroid carcinomas.
J Clin Invest 101:1296–1300.
210 FAGGIANO ET AL.
37. Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N 2001
Predominant intracellular overexpression of the Naþ=I
symporter (NIS) in a large sampling of thyroid cancer cases.
J Clin Endocrinol Metab 86:2697–2700.
38. Kaminski SM, Levy O, Salvador C, Dai G, Carrasco N 1994
Naþ=I symporter activity is present in membrane vesicles
from thyrotropin-deprived non-I-transporting cultured thy-
roid cells. Proc Natl Acad Sci USA 91:3789–3793.
39. Riedel C, Levy O, Carrasco N 2001 Post-transcriptional
regulation of the sodium=iodide symporter (NIS) by thyro-
tropin. J Biol Chem 276:21458–21463.
40. Trouttet-Masson S, Selmi-Ruby S, Bernier-Valentin F, Porra
V, Berger-Dutrieux N, Decaussin M, Peix JL, Perrin A,
Bournaud C, Orgiazzi J, Borson-Chazot F, Franc B, Rousset B
2004 Evidence for transcriptional and posttranscriptional
alterations of the sodium=iodide symporter expression in
hypofunctioning benign and malignant thyroid tumors. Am
J Pathol 165:25–34.
41. Skubis-Zegadlo J, Nikodemska A, Przytula E, Mikula M,
Bardadin K, Ostrowski J, Wenzel BE, Czarnocka B 2005
Expression of pendrin in benign and malignant thyroid tis-
sues. Br J Cancer 93:144–151.
42. Lacroix L, Nocera M, Mian C, Caillou B, Virion A, Dupuy C,
Filetti S, Bidart JM, Schlumberger M 2001 Expression of
nicotinamide adenine dinucleotide phosphate oxidase flavo-
protein Duox genes and proteins in human papillary and
follicular thyroid carcinomas. Thyroid 11:1017–1023.
43. Harach HR, Franssila KO 1988 Thyroglobulin immuno-
staining in follicular thyroid carcinoma: relationship to the
degree of differentiation and cell type. Histopathology 13:
43–54.
44. Tanaka K, Inoue H, Miki H, Masuda E, Kitaichi M, Komaki
K, Uyama T, Monden Y 1997 Relationship between prog-
nostic score and thyrotropin receptor (TSH-R) in papillary
thyroid carcinoma: immunohistochemical detection of
TSH-R. Br J Cancer 76:594–599.
45. Choi YL, Kim MK, Suh JW, Han J, Kim JH, Yang JH, Nam SJ
2005 Immunoexpression of HBME-1, high molecular weight
cytokeratin, cytokeratin 19, thyroid transcription factor-1,
and E-cadherin in thyroid carcinomas. J Korean Med Sci
20:853–859.
46. Fenton CL, Patel A, Burch HB, Tuttle RM, Francis GL 2001
Nuclear localization of thyroid transcription factor-1 corre-
lates with serum thyrotropin activity and may be increased
in differentiated thyroid carcinomas with aggressive clinical
course. Ann Clin Lab Sci 31:245–252.
47. Lacroix L, Michiels S, Mian C, Arturi F, Caillou B, Filetti S,
Schlumberger M, Bidart JM 2006 HEX, PAX-8 and TTF-1
gene expression in human thyroid tissues: a comparative
analysis with other genes involved in iodide metabolism.
Clin Endocrinol 64:398–404.
48. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC,
Goepfert H, Samaan NA 1990 Anaplastic carcinoma of the
thyroid. A clinicopathologic study of 121 cases. Cancer 66:
321–330.
49. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, Lee
MC, Cho BY 2001 Relationship between expression of the
sodium=iodide symporter and 131I uptake in recurrent le-
sions of differentiated thyroid carcinoma. Eur J Nucl Med
28:639–645.
50. Schlumberger M 1998 Papillary and follicular thyroid car-
cinoma. N Engl J Med 338:297–306.
51. Rosai J 2003 Immunohistochemical markers of thyroid tu-
mors: significance and diagnostic applications. Tumori 89:
517–519.
Address reprint requests to:
Martin Schlumberger, M.D.
Department of Nuclear Medicine and Endocrine Oncology
Institut Gustave-Roussy
39 rue C. Desmoulins
94805 Villejuif
France
E-mail: schlumbg@igr.fr
IMMUNOHISTOCHEMISTRY IN THYROID DISEASES 211

